| Literature DB >> 34463943 |
Jian-Hong Qi1, Fang-Xu Dong2, Xiao-Long Wang3,4,5.
Abstract
Paeonol, derived from natural plants (Moutan Cortex), has a wide range of biological effects, including anti-inflammatory and antitumor effects as well as favorable effects against cardiovascular and neurodegenerative diseases. The anti-inflammatory action is the main pharmacological activity of paeonol and has the greatest clinical relevance. However, the anti-inflammatory mechanism of paeonol has not been reported in sufficient detail. We systematically analyzed the anti-inflammatory mechanism of paeonol using network pharmacological databases and platforms, including TCMSP, Swiss TargetPrediction, OMIM, DrugBank, TTD, Jevnn, STRING11.0, and Metascape. Furthermore, we used high-throughput molecular docking method to prove the results of the above analyses, providing a reference for exploring the mechanism of paeonol and developing targeted drugs.Entities:
Keywords: Inflammation; Molecular docking; Network pharmacology; Paeonol; Target
Mesh:
Substances:
Year: 2021 PMID: 34463943 PMCID: PMC8405392 DOI: 10.1007/s11030-021-10301-8
Source DB: PubMed Journal: Mol Divers ISSN: 1381-1991 Impact factor: 3.364
Optimal binding energies between paeonol and core targets
| Rank | Target name | Protein name | PDB ID | Score (kcal/mol) |
|---|---|---|---|---|
| 1 | MMP9 | Matrix metalloproteinase-9 | 6ESM | − 7.4 |
| 2 | MMP13 | Collagenase 3 | 5B5O | − 7.1 |
| 3 | ALB | Albumin | 6YG9 | − 6.8 |
| 4 | PTGS2 | Prostaglandin G/H synthase 2 | 5F19 | − 6.7 |
| 5 | PTGS1 | Prostaglandin G/H synthase 1 | 6Y3C | − 6.7 |
| 6 | MMP3 | Stromelysin-1 | 1HY7 | − 6.6 |
| 7 | RARA | Retinoic acid receptor alpha | 3KMR | − 6.4 |
| 8 | MET | Hepatocyte growth factor receptor | 4R1V | − 6.3 |
| 9 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 3V98 | − 6.2 |
| 10 | MAPK8 | Mitogen-activated protein kinase 8 | 2XRW | − 6 |
| 11 | ESR1 | Estrogen receptor | 6VIG | − 5.8 |
| 12 | PTEN | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | 1D5R | − 5.7 |
| 13 | MAPK1 | Mitogen-activated protein kinase 1 | 4ZZN | − 5.5 |
| 14 | ESR2 | Estrogen receptor beta | 3OLL | − 5.4 |
| 15 | TTR | Transthyretin | 4D7B | − 5.3 |
| 16 | IL2 | Interleukin-2 | 4NEJ | − 5.1 |
| 17 | ELANE | Neutrophil elastase | 5ABW | − 5.1 |
| 18 | TNF | Tumor necrosis factor | 5UUI | − 4.9 |
| 19 | AKT1 | RAC-alpha serine/threonine-protein kinase | 1UNQ | − 4.7 |
| 20 | NFKBIA | NF-kappa-B inhibitor alpha | 6Y1J | − 4.7 |
| 21 | ICAM1 | Intercellular adhesion molecule 1 | 1IAM | − 4.7 |
| 22 | VCAM1 | Vascular cell adhesion protein 1 | 1VCA | − 4.6 |
| 23 | RELA | Transcription factor p65 | 6NV2 | − 3.4 |
Fig. 1Venn diagrams of paeonol-related targets and inflammation-related targets
Fig. 2PPI network for anti-inflammatory targets of paeonol. a Network nodes represent proteins: colored nodes mean the first shell of interactors. Node content: 3D structure of the protein. Edges of different colors represent protein–protein associations: light blue and purple edges mean known interactions (database & experiment); green, red, and blue edges mean predicted interactions (gene neighborhood, gene fusions, gene co-occurrence); yellow edges mean text mining; and black edges indicate co-expression. b The PPI network was processed by Cytoscape software: larger areas denote more important nodes. c Modules with potential biological significance in PPI
Fig. 3GO and KEGG analyses of paeonol anti-inflammatory activity. a represents biological processes, b represents cellular components, c represents molecular functions, D represents signaling pathways
Enrichment information of signaling pathways
| Signaling pathway | Count | Log10 (P) | Targets |
|---|---|---|---|
| TNF signaling pathway | 11 | − 20.00294635 | AKT1|ICAM1|MMP3|MMP9|NFKBIA|MAPK1|MAPK8|PTGS2|RELA|TNF|VCAM1 |
| IL-17 signaling pathway | 9 | − 16.04429079 | MMP3|MMP9|MMP13|NFKBIA|MAPK1|MAPK8|PTGS2|RELA|TNF |
| Hepatitis B | 8 | − 12.25489905 | AKT1|MMP9|NFKBIA|MAPK1|MAPK8|PTEN|RELA|TNF |
| Pathways in cancer | 10 | − 11.97434934 | AKT1|MET|MMP9|NFKBIA|MAPK1|MAPK8|PTEN|PTGS2|RARA|RELA |
| AGE-RAGE signaling pathway in diabetic complications | 7 | − 11.46555508 | AKT1|ICAM1|MAPK1|MAPK8|RELA|TNF|VCAM1 |
| Chagas disease (American trypanosomiasis) | 7 | − 11.37271885 | AKT1|IL2|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Toxoplasmosis | 7 | − 11.05505232 | AKT1|ALOX5|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Prolactin signaling pathway | 6 | − 10.35810608 | AKT1|ESR1|ESR2|MAPK1|MAPK8|RELA |
| Fluid shear stress and atherosclerosis | 7 | − 10.35077372 | AKT1|ICAM1|MMP9|MAPK8|RELA|TNF|VCAM1 |
| HTLV-I infection | 8 | − 10.24468526 | AKT1|ICAM1|IL2|NFKBIA|MAPK8|RELA|TNF|VCAM1 |
| Influenza A | 7 | − 9.746401964 | AKT1|ICAM1|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| NF-kappa B signaling pathway | 6 | − 9.543195864 | ICAM1|NFKBIA|PTGS2|RELA|TNF|VCAM1 |
| Endocrine resistance | 6 | − 9.51542753 | AKT1|ESR1|ESR2|MMP9|MAPK1|MAPK8 |
| T-cell receptor signaling pathway | 6 | − 9.329065252 | AKT1|IL2|NFKBIA|MAPK1|RELA|TNF |
| Toll-like receptor signaling pathway | 6 | − 9.303518428 | AKT1|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Th17 cell differentiation | 6 | − 9.228377407 | IL2|NFKBIA|MAPK1|MAPK8|RARA|RELA |
| Insulin resistance | 6 | − 9.228377407 | AKT1|NFKBIA|MAPK8|PTEN|RELA|TNF |
| Sphingolipid signaling pathway | 6 | − 8.970385519 | AKT1|MAPK1|MAPK8|PTEN|RELA|TNF |
| Osteoclast differentiation | 6 | − 8.715891959 | AKT1|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Hepatitis C | 6 | − 8.695791279 | AKT1|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Apoptosis | 6 | − 8.55937549 | AKT1|NFKBIA|MAPK1|MAPK8|RELA|TNF |
| Fc epsilon RI signaling pathway | 5 | − 8.326499522 | AKT1|ALOX5|MAPK1|MAPK8|TNF |
Fig. 4Target-signaling pathway network of paeonol anti-inflammatory activity. From the inside to the outside: the circle is target, the diamond is paeonol and inflammation, and the inverted triangle is the signaling pathway. Node size: larger nodes indicate more important ones
Characteristic parameters of target-signaling pathway network
| Type | Name | Degree | Closeness centrality |
|---|---|---|---|
| Target | RELA | 22 | 0.613636 |
| Target | MAPK8 | 22 | 0.613636 |
| Target | TNF | 21 | 0.6 |
| Target | AKT1 | 21 | 0.6 |
| Target | MAPK1 | 20 | 0.586957 |
| Target | NFKBIA | 18 | 0.5625 |
| Target | MMP9 | 9 | 0.473684 |
| Target | PTEN | 8 | 0.465517 |
| Target | IL2 | 8 | 0.465517 |
| Target | ICAM1 | 8 | 0.465517 |
| Target | VCAM1 | 7 | 0.457627 |
| Target | PTGS2 | 6 | 0.45 |
| Target | ALOX5 | 6 | 0.45 |
| Target | RARA | 5 | 0.442623 |
| Target | MET | 5 | 0.442623 |
| Target | MMP3 | 4 | 0.435484 |
| Target | MMP13 | 4 | 0.435484 |
| Target | ESR2 | 4 | 0.435484 |
| Target | ESR1 | 4 | 0.435484 |
| Target | TTR | 2 | 0.421875 |
| Target | TGM2 | 2 | 0.421875 |
| Target | PTPRC | 2 | 0.421875 |
| Target | PTPN22 | 2 | 0.421875 |
| Target | PTGS1 | 2 | 0.421875 |
| Target | HMOX1 | 2 | 0.421875 |
| Target | ELANE | 2 | 0.421875 |
| Target | CA2 | 2 | 0.421875 |
| Target | ALB | 2 | 0.421875 |
| Target | AHSA1 | 2 | 0.421875 |
| Target | ADRB2 | 2 | 0.421875 |
| Target | ACE | 2 | 0.421875 |
| Pathway | TNF signaling pathway | 17 | 0.514286 |
| Pathway | Prolactin signaling pathway | 12 | 0.469565 |
| Pathway | Pathways in cancer | 10 | 0.453782 |
| Pathway | IL-17 signaling pathway | 9 | 0.446281 |
| Pathway | Hepatitis B | 8 | 0.439024 |
| Pathway | HTLV-I infection | 8 | 0.439024 |
| Pathway | AGE-RAGE signaling pathway in diabetic complications | 7 | 0.432 |
| Pathway | Chagas disease (American trypanosomiasis) | 7 | 0.432 |
| Pathway | Toxoplasmosis | 7 | 0.432 |
| Pathway | Fluid shear stress and atherosclerosis | 7 | 0.432 |
| Pathway | Influenza A | 7 | 0.432 |
| Pathway | NF-kappa B signaling pathway | 6 | 0.418605 |
| Pathway | Endocrine resistance | 6 | 0.418605 |
| Pathway | T cell receptor signaling pathway | 6 | 0.425197 |
| Pathway | Toll-like receptor signaling pathway | 6 | 0.425197 |
| Pathway | Th17 cell differentiation | 6 | 0.425197 |
| Pathway | Insulin resistance | 6 | 0.425197 |
| Pathway | Sphingolipid signaling pathway | 6 | 0.425197 |
| Pathway | Osteoclast differentiation | 6 | 0.425197 |
| Pathway | Hepatitis C | 6 | 0.425197 |
| Pathway | Apoptosis | 6 | 0.425197 |
| Pathway | Fc epsilon RI signaling pathway | 5 | 0.418605 |
Fig. 5Docking diagram of paeonol with the top three targets. a paeonol with MMP9, b paeonol with MMP13, and c paeonol with ALB; 3D diagram on the left and the 2D diagram on the right show the positions of active pockets and the types of interactions